Xtant Medical (NYSEAMERICAN:XTNT) Stock Passes Above Two Hundred Day Moving Average – Should You Sell?

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) shares passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.38. Xtant Medical shares last traded at $0.36, with a volume of 209,214 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Craig Hallum set a $1.50 price target on shares of Xtant Medical and gave the company a “buy” rating in a report on Friday, October 18th.

Xtant Medical Stock Performance

The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.88 and a current ratio of 2.12. The company has a market capitalization of $50.04 million, a price-to-earnings ratio of -2.77 and a beta of 0.34.

Xtant Medical (NYSEAMERICAN:XTNT) last announced its earnings results on Tuesday, November 12th. The medical device company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). The business had revenue of $27.94 million during the quarter. Xtant Medical had a negative net margin of 15.45% and a negative return on equity of 37.07%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Xtant Medical stock. Evernest Financial Advisors LLC bought a new stake in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund bought 40,000 shares of the medical device company’s stock, valued at approximately $27,000. 69.33% of the stock is owned by hedge funds and other institutional investors.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.